Clinical trials: Monoclonal
Solid Tumor, Adult, Lymphoma
A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection in Patients With Solid Tumor or Lymphoma
This study is a first-in-class open-label phase I human clinical study to evaluate the safety and tolerability of HLX26 with escalated doses in the treatment of patients with advanced/metastatic solid tumors or lymphomas.
- Trial name
- NCT05078593
- Testing
- HLX26
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shanghai Henlius Biotech
Respiratory Syncytial Virus
A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of an extended half-life anti-respiratory syncytial virus (RSV) monoclonal antibody compared to placebo when administered to healthy preterm…
- Trial name
- MEDI8897 1b (NCT02290340)
- Testing
- MEDI8897 10 mg, MEDI8897 25 mg, MEDI8897 50 mg
- Where
- 13 sites in United States, Chile and 1 more
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Crohn's Disease
Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease
To evaluate the long-term maintenance of response, safety and tolerability of repeated administration of adalimumab in subjects with Crohn's disease who participated in and successfully completed Protocol M02-404 or Protocol…
- Trial name
- NCT00195715
- Testing
- Adalimumab
- Where
- 111 sites in United States, Australia and 13 more
- Volunteers
- 777 people
- Sponsor
- Abbott
Advanced Solid Tumors
A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors
The purpose of this study is to assess the safety, drug levels, immunogenicity and preliminary efficacy of BMS-986213 (nivolumab-relatlimab fixed-dose combination) in Chinese participants with advanced solid tumors.
- Trial name
- RELATIVITY 059 (NCT05134948)
- Testing
- BMS-986213
- Where
- 2 sites in China
- Volunteers
- 24 people
- Sponsor
- Bristol-Myers Squibb
Chronic Lymphocytic Leukemia
Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy
The purpose of this study is to determine the highest tolerated dose, safety and activity of HCD122 in patients with chronic lymphocytic leukemia who are relapsed after receiving prior treatment.
- Trial name
- NCT00108108
- Testing
- HCD122
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- Novartis Pharmaceuticals
Non-Hodgkin's Lymphoma
Expanded Access Study of Iodine-131 Anti-B1 Antibody
The primary objective of this study is to make Iodine-131 Anti-B1 Antibody more broadly available to patients. Secondary endpoints of the study will be to obtain additional information on the efficacy and safety of Iodine-131…
- Trial name
- NCT00022958
- Testing
- Iodine-131 Anti-B1 Antibody
- Where
- United States
- Sponsor
- Corixa Corporation
Ulcerative Colitis, Gastrointestinal Disease
Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis
The purpose of The PROSPECT Study is to evaluate an investigational medication for the treatment of moderate to severe ulcerative colitis.
- Conditions
- Ulcerative Colitis, Gastrointestinal Disease, Inflammatory Bowel Disease
- Trial name
- NCT00073047
- Testing
- Daclizumab
- Where
- 35 sites in United States, Belgium and 1 more
- Volunteers
- 150 people
- Sponsor
- Facet Biotech
Graves' Disease
Thyroid-Stimulating Hormone Receptor (TSHR) Blockade With REGN24493 in Adult Participants With Graves' Disease (GD)
This study will test an experimental Regeneron drug called REGN24493 hereby referred to as "study drug" to see if it can help treat Graves' disease.
- Trial name
- EMERGE (NCT07861152)
- Testing
- REGN24493
- Volunteers
- 45 people
- Sponsor
- Regeneron Pharmaceuticals
Shiga Toxin Producing Bacterial Infection
Study of Chimeric Monoclonal Antibodies to Shiga Toxins 1 and 2
This study is designed to evaluate the safety and efficacy of cαStx1 and cαStx2 administered concomitantly in children presenting early signs of Shiga Toxin-Producing Bacterial (STPB) Infection.
- Trial name
- NCT01252199
- Testing
- cαStx1/cαStx2
- Where
- 11 sites in Argentina, Chile and 1 more
- Volunteers
- 45 people
- Sponsor
- Thallion Pharmaceuticals
Healthy
Study to Evaluate Pharmacokinetics, Safety and Efficacy of CM310
This is a single-center, randomized, open study to evaluate the pharmacokinetics, safety and immunogenicity CM310 in healthy subjects.
- Trial name
- NCT05702450
- Testing
- CM310
- Where
- China
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Keymed Biosciences Co.Ltd
Lymphoma, Large-Cell, Anaplastic, Lymphoma, NK-cell
A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms
The purpose of this study is to assess the safety profile of brentuximab vedotin sequentially and in combination with multi-agent chemotherapy in front-line treatment for CD30-positive mature T-cell and NK-cell neoplasms…
- Conditions
- Lymphoma, Large-Cell, Anaplastic, Lymphoma, NK-cell, Lymphoma, T-cell
- Trial name
- NCT01309789
- Testing
- brentuximab vedotin, cyclophosphamide, prednisone
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 39 people
- Sponsor
- Seagen Inc.
Non-squamous Non-small-cell Lung Cancer
A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer
This trial is a randomized, double-blind, parallel-controlled, multicenter phase III clinical study. To evaluate the clinical efficacy of SIBP04 in patients with locally advanced, metastatic or recurrent non-squamous non-small…
- Trial name
- NCT05318443
- Testing
- SIBP04, Avastin, Paclitaxel
- Where
- China
- Volunteers
- 512 people
- Sponsor
- Shanghai Institute Of Biological Products
Multiple Sclerosis, Relapsing-Remitting
Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS
The humanised IgG4 monoclonal antibody GNbAC1 targets the envelope protein (Env) of the human endogenous multiple sclerosis-associated retrovirus (HERV-W MSRV), which may play a critical role in multiple sclerosis (MS).
- Trial name
- CHANGE-MS (NCT02782858)
- Testing
- GNbAC1
- Where
- 12 sites in Bulgaria, Croatia and 10 more
- Volunteers
- 270 people
- Sponsor
- GeNeuro SA
Acute Myeloid Leukemia
A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML
The purpose of this study is to assess whether there is a survival benefit with lintuzumab given in combination with low dose cytarabine versus low dose cytarabine and placebo in patients with AML.
- Trial name
- NCT00528333
- Testing
- Lintuzumab (SGN-33), Low dose cytarabine
- Where
- 20 sites in United States
- Volunteers
- 211 people
- Sponsor
- Seagen Inc.
COVID-19
A Study of Human Monoclonal Antibodies, BRII-196 and BRII-198
The aim of this phase 2 study is to evaluate the safety and efficacy of single dose IV infusion of BRII-196 and BRII-198 given as combination therapy in patients with severe COVID-19, and mild to moderate COVID-19 and…
- Trial name
- NCT04787211
- Testing
- BRII-196 and BRII-198
- Where
- 6 sites in China
- Volunteers
- 48 people
- Sponsor
- Brii Biosciences Limited
Cancer
Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors
This study will be used to determine the safety and tolerability of BMS-986016 administered alone and in combination with Nivolumab in subjects with advanced solid tumors.
- Trial name
- NCT02966548
- Testing
- Relatlimab, Nivolumab
- Where
- Japan
- Volunteers
- 35 people
- Sponsor
- Bristol-Myers Squibb
Neonatal Staphylococcal Sepsis
Safety and Pharmacokinetics Study in VLBW Neonates With BSYX-A110
"Phase I/II, Randomized, Double Blind, Placebo Controlled, Dose Escalating, Safety and Pharmacokinetics Study in Very Low Birth Weight Neonates of Four Doses of BSYX-A110 for the Prevention of S.
- Trial name
- N002 (NCT00631878)
- Testing
- Pagibaximab (formerly BSYX-A110)
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Biosynexus Incorporated
Acute Gout
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study
The purpose of the 12-week core study was to demonstrate that canakinumab given upon acute gout flares relieves the signs and symptoms and prevents recurrence of gout flares in patients with frequent flares of gout for whom…
- Trial name
- β-RELIEVED (NCT01029652)
- Testing
- Canakinumab 150 mg, Triamcinolone acetonide 40 mg
- Where
- 47 sites in Australia, Belgium and 15 more
- Volunteers
- 230 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Kidney Disease, Diabetic Nephropathy
A Study in Participants With Diabetic Kidney Disease
The purpose of this study is to determine if LY2382770 is safe and effective at protecting kidney function in participants with kidney disease due to diabetes.
- Conditions
- Diabetic Kidney Disease, Diabetic Nephropathy, Diabetic Glomerulosclerosis
- Trial name
- NCT01113801
- Testing
- LY2382770
- Where
- 78 sites in United States, Australia and 5 more
- Volunteers
- 417 people
- Sponsor
- Eli Lilly and Company
Brain Metastases From Solid Tumors
131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiation in Patients With Multiple Brain Metastases From Solid Tumors
The aim of this Proof of Concept study is to determine the therapeutic potential of the L19SIP antibody, labeled with the radionuclide 131I in combination with external beam radiation, for the treatment of patients with multiple…
- Trial name
- NCT01125085
- Testing
- 131I-L19SIP Radioimmunotherapy (RIT) in Combination With Whole Brain Radiation Therapy (WBRT)
- Where
- 10 sites in Italy, United Kingdom
- Volunteers
- 32 people
- Sponsor
- Philogen S.p.A.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.